[Mal diagnóstico y factores asociados con la resistencia a los medicamentos en la epilepsia generalizada idiopática]
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El diagnóstico erróneo y la medicación inadecuada afectan a casi el 20% de los pacientes con epilepsia generalizada idiopática (EIG). Los principales factores de riesgo para la epilepsia resistente a los medicamentos incluyen la epilepsia relacionada con el ciclo catamenial y los hallazgos específicos de EEG.
Área De La Ciencia
- Neurología
- Investigación sobre la epilepsia
- Neurociencia clínica
Sus Antecedentes
- La epilepsia generalizada idiopática (EIG) presenta desafíos de diagnóstico, lo que puede conducir a un diagnóstico erróneo y un tratamiento inadecuado.
- La comprensión de los factores de riesgo para la resistencia a los medicamentos es crucial para optimizar los resultados de los pacientes en IGE.
Objetivo Del Estudio
- Analizar los patrones de diagnóstico erróneo e identificar los factores de riesgo de resistencia a los medicamentos en pacientes con epilepsia generalizada idiopática (EIG).
- Evaluar la prevalencia del diagnóstico erróneo y el uso inadecuado de medicamentos en una cohorte de pacientes con EIG.
Principales Métodos
- Análisis retrospectivo de 188 pacientes con EIG diagnosticados de acuerdo con los criterios ILAE.
- Evaluación de las tasas de diagnóstico erróneo, uso inadecuado de medicamentos y resistencia a los medicamentos.
- Regresión logística multivariada para identificar los factores de riesgo de resistencia a los fármacos, teniendo en cuenta las características demográficas, clínicas y de EEG.
Principales Resultados
- El 18,6% de los pacientes fueron diagnosticados erróneamente con epilepsia focal y el 28,0% recibieron medicación inadecuada.
- El 15,4% de los pacientes desarrolló epilepsia resistente a los fármacos después de un seguimiento mediano de 3,8 años.
- Los factores de riesgo para la resistencia a los medicamentos incluyen epilepsia relacionada con el ciclo catamenial, tipos de convulsiones múltiples, descargas de EEG generalizadas y focales y alta carga de picos y ondas lentas.
Conclusiones
- El diagnóstico erróneo y la medicación inadecuada son problemas importantes en el manejo de la EIG.
- Una proporción notable de pacientes con EIG desarrollan epilepsia resistente a los medicamentos.
- La epilepsia relacionada con el ciclo catamenial, la diversidad de tipos de convulsiones y los hallazgos específicos de EEG son factores de riesgo clave para la resistencia a los medicamentos en la EIG.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Focal aware seizures: In these seizures, the person remains conscious...
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...